Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2025-12-24 @ 4:49 PM
NCT ID:
NCT01340950
Eligibility Criteria:
Inclusion Criteria:
* Men and women of at least 18 years of age.
* Ability and willingness of subject to give written informed consent.
* HIV-1 infection, as documented by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blot at any time prior to study entry. Plasma HIV-1 RNA is acceptable as an alternative confirmatory test.
* Antiretroviral drug-naïve, defined as ≤10 days of ART at any time prior to entry.
* Clinical HIV-1 RNA ≥1000 copies/mL obtained within 90 days of study screening.
* Clinical blood CD4+ cell count \< 350/mm3 (for men) or \<250/mm3 (for women) within 60 days of study screening.
* Performance within the expected normal range on the project's comprehensive, standardized battery of neuropsychological tests within 4 weeks.
* For women of child-bearing potential (WOCBP), negative serum or urine pregnancy test at screening and within 48 hours prior to initiating study medications.
Exclusion Criteria:
* Serious illness requiring systemic treatment or hospitalization within 4 weeks.
* Unacceptable laboratory values obtained within 4 weeks prior to study entry.
* Untreated syphilis.
* Child Pugh Class C hepatic impairment.
* Active Hepatitis B Virus infection.
* Known allergy/sensitivity to study drugs or their formulations.
* Severe or untreated conditions that could affect NP test performance.
* Such conditions include but are not limited to current substance use disorder, poorly controlled diabetes, uncontrolled seizure disorder, and any progressive CNS disorder (e.g., multiple sclerosis, CNS neoplasm) and evidence of acute intoxication or withdrawal, in the opinion of the study clinician.
* Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.
* Currently breast-feeding.
* Requirement for any medications that have an absolute contraindication with any study drugs. In addition, we will exclude people taking rifampin.
* Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness.
* Prior use of nucleoside analogues, such as tenofovir, adefovir, or lamivudine, for treatment of hepatitis B for greater than 8 weeks while the subject was known to be HIV-infected.
* Any condition that, in the opinion of the investigators, would compromise the subject's ability to participate in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT01340950
Study Brief:
Protocol Section:
NCT01340950